Find clinical trials for Leukemia in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia

Acute Myeloid Leukemia

Lymphoid Leukemia

B-Cell Chronic Lymphocytic Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Lymphoma

Myelodysplastic Syndromes

Leukemia trials near Berlin, BE, DEU:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...

Enrolling

Acute Leukemia of Ambiguous Lineage

Mixed Phenotype Acute Leukemia

Drug: Ziftomenib

Drug: Itraconazole

Phase 1, Phase 2

Kura Oncology

Berlin, Germany and 55 other locations

Locations recently updated

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (TUSCANY)

in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...

Enrolling

Leukemia, Myeloid, Acute

Chronic Myelomonocytic Leukemia

Drug: Venetoclax Oral Tablet

Drug: Tuspetinib

Phase 1, Phase 2

Aptose Biosciences

Berlin, Berlin, Germany and 33 other locations

CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

participants with previously treated chronic phase - chronic myeloid leukemia (CP-CML).The study has two parts: Part 1 of the trial (Dose Es...

Enrolling

Chronic Myeloid Leukemia

Chronic Myeloid Leukemia, Chronic Phase

Drug: TERN-701

Phase 1

Terns Pharmaceuticals

Berlin, Germany and 39 other locations

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia...

Active, not recruiting

Leukemia, Myeloid, Acute

Drug: Azacitidine

Drug: AG-120

Phase 1, Phase 2

Celgene

Berlin, Germany and 48 other locations

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retr...

Enrolling

Chronic Lymphocytic Leukemia (CLL)

Drug: Venetoclax

Drug: Obinutuzumab

Phase 2

AbbVie

Berlin, Germany and 55 other locations

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (453 Ph1 CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how wel...

Active, not recruiting

Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Drug: Obinutuzumab

Drug: ABBV-453

Phase 1

AbbVie

Berlin, Germany and 20 other locations

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

generation (2G) Tyrosine Kinase Inhibitor (TKI) nilotinib (300 mg BID), in adult patients with newly diagnosed Positive Chronic Myelogenous Leukemia...

Active, not recruiting

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Drug: Nilotinib

Drug: Asciminib

Phase 3

Novartis

Berlin, Germany and 119 other locations

Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy (VENAZA-5S)

Acute myeloid leukemia (AML): continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cycle = standard of care for ...

Enrolling

Acute Myeloid Leukemia (AML)

Drug: VEN+AZA-5

Phase 2

University of Leipzig

Berlin, Germany and 9 other locations

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia...

Enrolling

LGLL - Large Granular Lymphocytic Leukemia

Aggressive NK Cell Leukemia

Drug: DR-01

Phase 1, Phase 2

Dren Bio

Berlin, Germany and 34 other locations

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (...

Enrolling

Leukemia, Myeloid, Acute

Drug: Cytarabine

Drug: Bleximenib

Phase 1

Janssen (J&J Innovative Medicine)

Berlin, Germany and 32 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Leukemia in .css-epvm6{white-space:nowrap;}Berlin, BE

Related conditions:

Leukemia trials near Berlin, BE, DEU:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (TUSCANY)

CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (453 Ph1 CLL)

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy (VENAZA-5S)

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Find clinical trials for Leukemia in Berlin, BE